Abstract
Type-specific vaccines containing heat-inactivated herpes simplex hominis virus type 1 or 2 have been developed for the treatment of herpes simplex genitalis. When patients with recurrent herpes genitalis were treated with the type 2 vaccine the clinical course of the disease improved and the eruption-free interval was extended. In severe cases, especially in permanent genital herpes, the concurrent administration of vaccine and immunoglobulin concentrates improved the clinical course of the disease. Antibody titres and the in-vitro stimulation of lymphocytes with phytohaemagglutinin or herpes simplex hominis virus antigens remained constant during administration of the vaccine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cappel R. Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations. Arch Virol. 1976;52(1-2):29–35. doi: 10.1007/BF01317862. [DOI] [PubMed] [Google Scholar]
- Jarisch R., Sandor I. MIF in der Therapiekontrolle von Herpes simplex recidivans: Bhandlung mit Levamisole, BCG, Urushiol und Herpes Antigen Vaccine. Arch Dermatol Res. 1977 Apr 27;258(2):151–159. doi: 10.1007/BF00561620. [DOI] [PubMed] [Google Scholar]
- Koinis G., Wüthrich B. Bericht über eine Herpes-simplex-Vakzine (Lupidon H und G) für die Behandlung des rezidivierenden Herpes simplex. Schweiz Rundsch Med Prax. 1975 Sep 16;64(37):1176–1179. [PubMed] [Google Scholar]
- Lopez C., O'Reilly R. J. Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay. J Immunol. 1977 Mar;118(3):895–902. [PubMed] [Google Scholar]
- Nasemann T. Herpes simplex type II vaccine: the favorable European experience. Int J Dermatol. 1976 Oct;15(8):587–588. doi: 10.1111/j.1365-4362.1976.tb04893.x. [DOI] [PubMed] [Google Scholar]
- O'Reilly R. J., Chibbaro A., Anger E., Lopez C. Cell-mediated immune responses in patients with recurrent Herpes Simplex infections. II. Infection-associated deficiency of lymphokine production in patients with recurrent herpes labialis or herpes progenitalis. J Immunol. 1977 Mar;118(3):1095–1102. [PubMed] [Google Scholar]
- Raab W. Spezifische und unspezifische Immunstimulation bei Herpes simplex rezidivans. Z Hautkr. 1977 May 15;52(10):565–572. [PubMed] [Google Scholar]
- Remy W., Antoniadis G., Bockendahl H., Remy B. Antikörpertiter--Verläufe bei Patienten mit rezidivierenden Herpes simplex Virus-Infektionen unter Vakzinationen mit hitzeinaktivierten Herpes Viren. Z Hautkr. 1976 Feb 1;51(3):103–107. [PubMed] [Google Scholar]
- Wassilew S. W., Koch I. Der Lymphocytentransformationstest bei Patienten mit rezidivierenden Herpes simplex hominis-Erkrankungen. Arch Dermatol Res. 1978 Aug 28;262(3):267–274. doi: 10.1007/BF00447363. [DOI] [PubMed] [Google Scholar]
- Weitgasser H. Kontrollierte klinische Studie mit den Herpes-Antigenen LUPIDON H und LUPIDON G. Z Hautkr. 1977 Jun 1;52(11):625–628. [PubMed] [Google Scholar]